NAMSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NAMSW
NewAmsterdam Pharma Co N.V.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$20.47+0.64 (+3.23%)
Close on Oct 19, 2026
- Market cap
- $2.53B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns NewAmsterdam Pharma's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
1 buys · 42 sales
Net sold $61.77M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| ForGrowth NAP B.V. | 9,316,914 | 8.30% | 13D (active) amendment | Sep 26, 2025 |
| James N. Topper | 7,327,937 | 6.50% | 13D (active) amendment | Aug 18, 2025 |
| Shabet Rose Sharon | 6,978,534 | 6.50% | 13G (passive) amendment | Dec 31, 2024 |
| Abigail P. Johnson | 6,412,984 | 5.70% | 13G (passive) | Dec 31, 2025 |
| Capital World Investors | 12,188,377 | 10.40% | 13G (passive) amendment | May 29, 2026 |
| BCIP Life Sciences Associates, LP | 11,422,504 | 9.99% | 13D (active) amendment | Nov 5, 2025 |
| Rajeev Shah | 11,063,125 | 9.90% | 13G (passive) amendment | Mar 31, 2025 |
| RA Capital Management, L.P. | 10,875,454 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Frazier Life Sciences Public Fund, L.P. | 10,424,224 | 8.70% | 13D (active) amendment | Sep 18, 2026 |
| FMR LLC | 10,339,663 | 8.80% | 13G (passive) amendment | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Michael H. Davidson | Chief Executive Officer, Director | 1,078,638 | Sep 15, 2026 |
| Johannes Jacob Pieter Kastelein | Chief Scientific Officer, Director | 247,802 | Aug 25, 2026 |
| Robert William Gunning | Vice President, Controller | 3,200 | Sep 3, 2026 |
| Louise Frederika Kooij | Chief Accounting Officer | 49,353 | Jul 22, 2026 |
| Mayur Ian Somaiya | Chief Financial Officer | 98,166 | Jan 22, 2026 |
| Douglas F. Kling | Chief Operating Officer | 44,000 | Jul 17, 2025 |
| Michael F. Marino III | See Remarks | 55,000 | Jun 3, 2025 |
| Juliette Berangere Audet | See Remarks | 15,104 | May 2, 2025 |
| William A. Jones Jr | Chief Commercial Officer | 43,000 | Jan 7, 2025 |
| John W. Smither | Director | 8,760 | Sep 9, 2026 |
| Louis G. Lange | Director | 10,806 | Mar 12, 2026 |
| der Kamp Hilde Johanna van | Director | 10,360 | Jan 9, 2026 |
| William Lewis | Director | 10,360 | Jan 9, 2026 |
| Mark C. McKenna | Director | 10,360 | Jan 9, 2026 |
| Adele M. Gulfo | Director | 14,260 | Jan 9, 2026 |
| James N. Topper | Director | 6,829,524 | Sep 17, 2025 |
| Growth Opportunities Fund I. Cooperatief U.A. Forbion | 10% owner | – | Jan 2, 2025 |
| Growth Management B.V. Forbion | 10% owner | 11,316,472 | Jan 2, 2025 |
| NAP B.V. ForGrowth | 10% owner | 10,656,172 | Jan 2, 2025 |
| IV Management B.V. Forbion | 10% owner | 10,760,928 | Jan 2, 2025 |
| Capital Fund IV Cooperatief U.A. Forbion | 10% owner | 10,686,018 | Jan 2, 2025 |
| Bain Capital Life Sciences III General Partner, LLC | 10% owner | – | Dec 17, 2024 |
| BCLS Fund III Investments, LP | 10% owner | – | Dec 17, 2024 |
| Bain Capital Life Sciences Investors II, LLC | 10% owner | – | Dec 17, 2024 |
| BCIP Life Sciences Associates, LP | 10% owner | – | Dec 17, 2024 |
| BCLS II Investco, LP | 10% owner | – | Dec 17, 2024 |
| Bain Capital Life Sciences Investors, LLC | 10% owner | – | Dec 17, 2024 |
| BCLS II Investco (GP), LLC | 10% owner | – | Dec 17, 2024 |
| Bain Capital Life Sciences Fund II, L.P. | 10% owner | – | Dec 17, 2024 |
| Bain Capital Life Sciences Fund III, L.P. | 10% owner | 10,473,913 | Dec 17, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael H. Davidson Chief Executive Officer, Director | Sep 14, 2026 | Buy | +10,000 | $22.65 | $226.50K | 792,923 |
| John W. Smither Director | Sep 4, 2026 | Sale | −1,600 | $25.32 | $40.51K | 8,760 |
| Robert William Gunning Vice President, Controller | Sep 1, 2026 | Award | +3,200 | – | – | 3,200 |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Aug 24, 2026 | Option exercise | +125,000 | – | – | 194,302 |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Aug 24, 2026 | Sale(10b5-1 plan) | −125,000 | $26.91 | $3.36M | 69,302 |
| Louise Frederika Kooij Chief Accounting Officer | Jul 20, 2026 | Option exercise | +25,000 | $11.90 | $297.50K | 49,353 |
| Louise Frederika Kooij Chief Accounting Officer | Jul 20, 2026 | Option exercise | +80,000 | $11.17 | $893.60K | 129,353 |
| Louise Frederika Kooij Chief Accounting Officer | Jul 20, 2026 | Sale(10b5-1 plan) | −70,200 | $29.96 | $2.10M | 59,153 |
| Louise Frederika Kooij Chief Accounting Officer | Jul 20, 2026 | Sale(10b5-1 plan) | −31,885 | $31.05 | $990.03K | 27,268 |
| Louise Frederika Kooij Chief Accounting Officer | Jul 20, 2026 | Sale(10b5-1 plan) | −2,915 | $31.71 | $92.43K | 24,353 |
| Louise Frederika Kooij Chief Accounting Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −39,700 | $30.20 | $1.20M | 24,653 |
| Louise Frederika Kooij Chief Accounting Officer | Jun 22, 2026 | Option exercise | +25,000 | $10.90 | $272.50K | 49,353 |
| Louise Frederika Kooij Chief Accounting Officer | Jun 22, 2026 | Option exercise | +15,000 | $11.90 | $178.50K | 64,353 |
| Louise Frederika Kooij Chief Accounting Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −300 | $30.73 | $9.22K | 24,353 |
| Louise Frederika Kooij Chief Accounting Officer | May 26, 2026 | Option exercise | +60,000 | $10.00 | $600.00K | 84,353 |
| Louise Frederika Kooij Chief Accounting Officer | May 26, 2026 | Sale(10b5-1 plan) | −65,000 | $35.69 | $2.32M | 24,353 |
| Louise Frederika Kooij Chief Accounting Officer | May 26, 2026 | Option exercise | +5,000 | $10.90 | $54.50K | 89,353 |
| Louis G. Lange Director | Mar 11, 2026 | Sale | −44,173 | $30.41 | $1.34M | 10,806 |
| Louis G. Lange Director | Mar 11, 2026 | Sale | −446 | $31.23 | $13.93K | 10,360 |
| Louis G. Lange Director | Mar 9, 2026 | Option exercise | +44,619 | $11.50 | $513.12K | 54,979 |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Mar 9, 2026 | Option exercise | +101,409 | – | – | 170,711 |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −101,409 | $30.29 | $3.07M | 69,302 |
| Louis G. Lange Director | Mar 6, 2026 | Sale | −28,186 | $29.41 | $828.95K | 0 |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Mar 6, 2026 | Sale(10b5-1 plan) | −94,124 | $30.32 | $2.85M | 69,302 |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Mar 6, 2026 | Option exercise | +94,124 | – | – | 163,426 |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Mar 5, 2026 | Sale(10b5-1 plan) | −104,467 | $30.30 | $3.17M | 69,302 |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Mar 5, 2026 | Option exercise | +104,467 | – | – | 173,769 |
| Michael H. Davidson Chief Executive Officer, Director | Mar 2, 2026 | Option exercise | +443,707 | – | – | 617,851 |
| Michael H. Davidson Chief Executive Officer, Director | Mar 2, 2026 | Sale | −443,707 | $33.25 | $14.75M | 174,144 |
| Michael H. Davidson Chief Executive Officer, Director | Feb 26, 2026 | Sale(10b5-1 plan) | −17,924 | $34.44 | $617.30K | 174,144 |
| Michael H. Davidson Chief Executive Officer, Director | Feb 26, 2026 | Sale(10b5-1 plan) | −165,408 | $33.63 | $5.56M | 477,783 |
| Michael H. Davidson Chief Executive Officer, Director | Feb 26, 2026 | Option exercise | +183,332 | – | – | 643,191 |
| Michael H. Davidson Chief Executive Officer, Director | Feb 25, 2026 | Sale(10b5-1 plan) | −1,300 | $36.68 | $47.68K | 459,859 |
| Michael H. Davidson Chief Executive Officer, Director | Feb 25, 2026 | Sale(10b5-1 plan) | −10,436 | $35.96 | $375.28K | 461,159 |
| Michael H. Davidson Chief Executive Officer, Director | Feb 25, 2026 | Sale(10b5-1 plan) | −46,517 | $35.11 | $1.63M | 471,595 |
| Michael H. Davidson Chief Executive Officer, Director | Feb 25, 2026 | Option exercise | +58,253 | – | – | 518,112 |
| Michael H. Davidson Chief Executive Officer, Director | Feb 24, 2026 | Sale(10b5-1 plan) | −3,161 | $36.46 | $115.25K | 459,859 |
| Michael H. Davidson Chief Executive Officer, Director | Feb 24, 2026 | Sale(10b5-1 plan) | −61,547 | $36.13 | $2.22M | 463,020 |
| Michael H. Davidson Chief Executive Officer, Director | Feb 24, 2026 | Option exercise | +64,708 | – | – | 524,567 |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Feb 20, 2026 | Sale | −14,692 | $35.00 | $514.22K | 84,289 |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer, Director | Feb 20, 2026 | Sale | −30,789 | $35.46 | $1.09M | 53,500 |
| Louise Frederika Kooij Chief Accounting Officer | Jan 28, 2026 | Sale(10b5-1 plan) | −32,612 | $31.80 | $1.04M | 24,353 |
| Louise Frederika Kooij Chief Accounting Officer | Jan 28, 2026 | Option exercise | +32,612 | $10.90 | $355.47K | 56,965 |
| Louise Frederika Kooij Chief Accounting Officer | Jan 27, 2026 | Option exercise | +39,816 | $10.90 | $433.99K | 64,169 |
| Louise Frederika Kooij Chief Accounting Officer | Jan 27, 2026 | Sale(10b5-1 plan) | −39,816 | $32.62 | $1.30M | 24,353 |
| Louise Frederika Kooij Chief Accounting Officer | Jan 26, 2026 | Sale(10b5-1 plan) | −309 | $33.45 | $10.34K | 24,353 |
| Louise Frederika Kooij Chief Accounting Officer | Jan 26, 2026 | Sale(10b5-1 plan) | −34,091 | $32.77 | $1.12M | 24,662 |
| Louise Frederika Kooij Chief Accounting Officer | Jan 26, 2026 | Option exercise | +34,400 | $10.90 | $374.96K | 58,753 |
| Louise Frederika Kooij Chief Accounting Officer | Jan 23, 2026 | Sale(10b5-1 plan) | −12,767 | $34.37 | $438.80K | 24,353 |
| Louise Frederika Kooij Chief Accounting Officer | Jan 23, 2026 | Sale(10b5-1 plan) | −25,405 | $33.44 | $849.54K | 37,120 |
| Louise Frederika Kooij Chief Accounting Officer | Jan 23, 2026 | Option exercise | +38,172 | $10.90 | $416.07K | 62,525 |
| Mayur Ian Somaiya Chief Financial Officer | Jan 21, 2026 | Option exercise | +39,784 | $9.26 | $368.40K | 98,166 |
| Mayur Ian Somaiya Chief Financial Officer | Jan 21, 2026 | Sale(10b5-1 plan) | −15,422 | $33.25 | $512.78K | 82,744 |
| Mayur Ian Somaiya Chief Financial Officer | Jan 21, 2026 | Sale(10b5-1 plan) | −24,362 | $33.80 | $823.44K | 58,382 |
| Mayur Ian Somaiya Chief Financial Officer | Jan 20, 2026 | Sale(10b5-1 plan) | −900 | $30.64 | $27.58K | 117,698 |
| Mayur Ian Somaiya Chief Financial Officer | Jan 20, 2026 | Sale(10b5-1 plan) | −39,712 | $31.78 | $1.26M | 77,986 |
| Mayur Ian Somaiya Chief Financial Officer | Jan 20, 2026 | Sale(10b5-1 plan) | −19,604 | $32.38 | $634.78K | 58,382 |
| Mayur Ian Somaiya Chief Financial Officer | Jan 20, 2026 | Option exercise | +60,216 | $9.26 | $557.60K | 118,598 |
| Louis G. Lange Director | Jan 7, 2026 | Award | +3,400 | – | – | 10,360 |
| William Lewis Director | Jan 7, 2026 | Award | +3,400 | – | – | 10,360 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Johannes Jacob Pieter Kastelein Affiliate | Aug 25, 2026 | 250,000 | $6.97M | Aug 25, 2026 | Option Exercise |
| Johannes Jacob Pieter Kastelein Affiliate | Aug 24, 2026 | 125,000 | $3.48M | Aug 24, 2026 | Option Exercise |
| Kooij Louise Officer | May 26, 2026 | 210,000 | $7.44M | May 26, 2026 | Stock Option Exercise |
| G. Lange Louis Affiliate | Mar 11, 2026 | 44,619 | $1.40M | Mar 11, 2026 | Warrant Exercise |
| G. Lange Louis Affiliate | Mar 6, 2026 | 28,186 | $878.84K | Mar 6, 2026 | RSU Award |
| Johannes Jacob Pieter Kastelein Affiliate | Mar 5, 2026 | 300,000 | $9.35M | Mar 2, 2026 | Option Exercise |
| H. Davidson Michael Affiliate | Mar 2, 2026 | 443,707 | $15.73M | Mar 2, 2026 | Option Exercise |
| H. Davidson Michael Affiliate | Feb 24, 2026 | 750,000 | $27.13M | Feb 24, 2026 | Option Exercise |
| Johannes Jacob Pieter Kastelein Officer, Director | Feb 20, 2026 | 45,481 | $1.58M | Feb 20, 2026 | Vesting of RSU Grant |
| Somaiya Mayur Affiliate | Jan 20, 2026 | 200,000 | $6.33M | Jan 20, 2026 | Stock Option Exercise |
| Davidson Michael affiliate | Jan 7, 2026 | 11,582 | $410.89K | Jan 7, 2026 | Vesting of RSU Grant |
| F. Kling Douglas Affiliate | Jan 6, 2026 | 300,000 | $10.04M | Jan 6, 2026 | Stock Option Exercise |
| Ian Somaiya Mayur affiliate | Jan 5, 2026 | 5,118 | $170.17K | Jan 5, 2026 | Vesting of RSU Grant |
| Kastelein Johannes Affiliate | Jan 5, 2026 | 6,000 | $199.50K | Jan 5, 2026 | Vesting of RSU Grant |
| Kooij Louise affiliate | Jan 5, 2026 | 2,647 | $88.01K | Jan 5, 2026 | Vesting of RSU Grant |